Topaz Pharmaceuticals is a specialty pharmaceutical company developing a topical prescription product, Sklice, for the treatment of head lice. Topaz Pharmaceuticals was acquired by Sanofi.
Region: North America
Tetraphase Pharmaceuticals
Tetraphase (NASDAQ: TTPH) is a biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections; its lead product XERAVATM (eravacycline) is approved for the treatment of complicated intra-abdominal infections by the FDA and EMA. Tetraphase Pharmaceuticals was acquired by La Jolla Pharmaceutical Company.
Symbiomix
Symbiomix developed the first oral, single dose treatment in the United States for bacterial vaginosis (BV), a common gynecological infection that increases the risk of serious health problems. Symbiomix was acquired by Lupin Pharmaceuticals.
ReGenX Biosciences
ReGenX Biosciences (NASDAQ: RGNX) is a leading AAV (adeno-associated virus) gene therapy company with a broad platform technology based on its proprietary NAV vector technology platform.
Proteostasis Therapeutics
Proteostasis Therapeutics is a drug discovery company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing. Proteostasis Therapeutics went public in 2016 (NASDAQ: PTI). The company merged with Yumanity Therapeutics in 2020 and is no longer traded with the ticker symbol PTI.
NextWave Pharmaceuticals
NextWave Pharmaceuticals is a specialty pharmaceutical company seeking to create and promote differentiated products in the pediatric market. NextWave Pharmaceuticals was acquired by Pfizer.
Mersana Therapeutics
Mersana Therapeutics (NASDAQ: MRSN) has its lead product candidate, XMT-1536, in clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC, and other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.
LigoCyte
LigoCyte Pharmaceuticals was a vaccine discovery and development company with a first-in-class vaccine for norovirus, a pathogen that is a leading cause of viral gastroenteritis (stomach flu). LigoCyte Pharmaceuticals was acquired by Takeda.
Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (NASDAQ: IRWD) developed linaclotide, a first-in-class therapy that received FDA approval for both irritable bowel syndrome and chronic constipation.
Ikano Therapeutics
Ikano Therapeutics is a specialty pharmaceutical company focused on developing Midazolam Nasal Spray (USL261) for acute repetitive seizures. Ikano was acquired by UCB.